Republican National Platform Embraces Medicare Transformation, FDA Reform
This article was originally published in The Pink Sheet Daily
Executive Summary
The platform signals party support for converting Medicare from a “defined benefit” to a “defined contribution” program, a change supported by the biopharmaceutical industry. It also calls for greater predictability and efficiency in the FDA review process.
You may also be interested in...
FDASIA Study Mandates Focus On Performance, But Could Slow Reviews
Advocates for the agency worry that while each of the performance assessments seems reasonable individually, together the reports could burden staff to the point of pulling some from application reviews or other tasks to help complete them.
Medicare Reform Using Part D Model Is Advocacy Priority For PhRMA – Castellani
For PhRMA, supporting a move toward privatizing Medicare is a tactic that may help avoid the establishment of new price controls in the system, like the often-discussed mandated drug rebates in Part D.
“Breakthrough” Designation Another Harmonization Opportunity, Woodcock Says
An agreement with the European Medicines Agency likely would be necessary for therapies designated as breakthroughs to ensure expedited clinical program would be accepted in both jurisdictions.